Dr Reddys Laboratories has reported results for the quarter ended June 30, 2013.
The company’s net profit declined by 63.49% at Rs 64.86 crore for the quarter as compared to Rs 177.66 crore for the same quarter in the previous year. Total income of the company has increased by 1.09% at Rs 1854.93 crore for quarter under review as compared to Rs 1834.94 crore for the quarter ended June 30, 2012.
On consolidated basis, the Group’s net profit after taxes rose by 7.45% at Rs 360.93 crore for the quarter under review as compared to Rs 335.98 crore for the June quarter of the previous year. Its total income has increased by 12.49% to Rs 2882.48 crore in Q1FY14 against Rs 2562.46 crore in Q1FY13.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.70 |
| Dr. Reddys Labs. | 1356.85 |
| Cipla | 1465.15 |
| Zydus Lifesciences | 1112.20 |
| Lupin | 2420.15 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: